<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00647855</url>
  </required_header>
  <id_info>
    <org_study_id>LEVO-0323</org_study_id>
    <nct_id>NCT00647855</nct_id>
  </id_info>
  <brief_title>Fasting Study of Levothyroxine Sodium Tablets 300 μg to Synthroid® Tablets 300 μg</brief_title>
  <official_title>Single-Dose Fasting In Vivo Bioequivalence Study of Levothyroxine Sodium Tablets (300 μg; Mylan) to Synthroid® Tablets (300 μg; Abbott) in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mylan Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The objective of this study was to investigate the bioequivalence of Mylan's levothyroxine&#xD;
      sodium 300 μg tablets to Abbott's Synthroid® 300 μg tablets following a single 600 μg (2 x&#xD;
      300 μg) dose administered in healthy volunteers under fasting conditions. Single-dose&#xD;
      pharmacokinetic parameters for baseline corrected total L-thyroxine and non-baseline&#xD;
      corrected total L-triiodothyronine were calculated using noncompartmental techniques.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">June 2003</completion_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence</measure>
    <time_frame>within 30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levothyroxine Sodium Tablets 300 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Synthroid® Tablets 300 μg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine Sodium Tablets 300 μg</intervention_name>
    <description>2x300mcg, single dose fasting</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Synthroid® Tablets 300 μg</intervention_name>
    <description>2x300mcg, single dose fasting</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18-50 years.&#xD;
&#xD;
          2. Sex: Men and/or non-pregnant, non-lactating women.&#xD;
&#xD;
               1. Women of childbearing potential must have negative serum β human chorionic&#xD;
                  gonadotropin (HCG) pregnancy tests performed within 14 days prior to of the study&#xD;
                  and on the evening prior to each dose administration. An additional serum (β HCG)&#xD;
                  pregnancy test will be performed upon completion of the study.&#xD;
&#xD;
               2. Women of childbearing potential must practice abstinence or be using an&#xD;
                  acceptable form of contraception throughout the duration of the study. Oral&#xD;
                  contraceptives are not to be used within 3 months prior to dosing and throughout&#xD;
                  the course of the study due to the fact that they increase serum TBG&#xD;
                  concentrations, and therefore, elevate T4. Acceptable forms of contraception&#xD;
                  include the following:&#xD;
&#xD;
                    1. intrauterine device in place for at least 3 months prior to the start of the&#xD;
                       study and remaining in place during the study period, or&#xD;
&#xD;
                    2. barrier methods containing or used in conjunction with a spermicidal agent,&#xD;
                       or&#xD;
&#xD;
                    3. postmenopausal accompanied with a documented postmenopausal course of at&#xD;
                       least one year or surgical sterility (tubal ligation, oophorectomy or&#xD;
                       hysterectomy).&#xD;
&#xD;
          3. Weight: At least 60 kg (132 lbs) for men and 48 kg (106 lbs) for women, and within 15%&#xD;
             of Ideal Body Weight (IBW), as referenced by the Table of &quot;Desirable Weights of&#xD;
             Adults&quot; Metropolitan Life Insurance Company, 1983 (See Part II Administrative Aspects&#xD;
             of Bioequivalence Protocols).&#xD;
&#xD;
          4. All subjects should be judged normal (euthyroid) and healthy during a prestudy medical&#xD;
             evaluation (physical examination, laboratory evaluation, blood chemistry, serum T4&#xD;
             (free and total), serum T3 (total only), serum thyroid-stimulating hormone (TSH),&#xD;
             serum thyroxine-binding globulin (TBG), hepatitis B and hepatitis C tests, HIV test,&#xD;
             12-lead ECG, and urine drug screen including amphetamine, barbiturates,&#xD;
             benzodiazepine, cannabinoid, cocaine, opiate screen, phencyclidine, and methadone)&#xD;
             performed within 14 days of the initial dose of study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Institutionalized subjects will not be used.&#xD;
&#xD;
          2. Social Habits:&#xD;
&#xD;
               1. Use of any tobacco products within 1 year of the initial study drug&#xD;
                  administration.&#xD;
&#xD;
               2. Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage&#xD;
                  within the 48 hours prior to the initial dose of study medication.&#xD;
&#xD;
               3. Ingestion of any vitamins within the 48 hours prior to the initial dose of the&#xD;
                  study medication.&#xD;
&#xD;
               4. Any change in dietary or exercise habits throughout the duration of the study.&#xD;
&#xD;
          3. Medications:&#xD;
&#xD;
               1. Use of any medication within the last 30 days prior to the initial dose of study&#xD;
                  medication, during the study or during the washout period. These may include but&#xD;
                  is not limited to: infant soybean formula, steroids, salicylates, androgenic or&#xD;
                  estrogenic hormones including oral contraceptives; preparations containing&#xD;
                  iodine, such as vitamins; oral anti-diabetic agents; all resins for lowering of&#xD;
                  cholesterol, such as cholestyramine; sucralfate, propranolol, amiodarone,&#xD;
                  phenytoin, carbamazepine, furosemide; aluminum-containing antacids, including&#xD;
                  aluminum hydroxide; rifampin, calcium channel blockers and ferrous sulfate.&#xD;
&#xD;
               2. Use of any medication known to alter hepatic enzyme activity within 28 days prior&#xD;
                  to the initial dose of study medication.&#xD;
&#xD;
          4. Diseases:&#xD;
&#xD;
               1. History of any significant chronic disease and/or hepatitis.&#xD;
&#xD;
               2. History of drug and/or alcohol abuse.&#xD;
&#xD;
               3. Acute illness at the time of either the prestudy medical evaluation or dosing.&#xD;
&#xD;
               4. History of any thyroid disease.&#xD;
&#xD;
               5. Subjects with any underlying medical condition known to interfere with the&#xD;
                  absorption or metabolism of thyroid hormones.&#xD;
&#xD;
          5. Abnormal and clinically significant laboratory test results:&#xD;
&#xD;
               1. Clinically significant deviation from the Guide for Clinically Relevant&#xD;
                  Abnormalities (See Part II Administrative Aspects of Bioavailability Protocols).&#xD;
&#xD;
               2. Abnormal and clinically relevant ECG tracing.&#xD;
&#xD;
               3. Abnormal thyroid function tests.&#xD;
&#xD;
          6. Donation or loss of a significant volume of blood or plasma (&gt; 450 ml) within 28 days&#xD;
             prior to the initial dose of study medication.&#xD;
&#xD;
          7. Subjects who received any surgical treatment within 6 months prior to the initial dose&#xD;
             of study medication.&#xD;
&#xD;
          8. Subjects with known allergies or hypersensitivity to thyroid preparations.&#xD;
&#xD;
          9. Subjects who have received an investigational drug within 30 days prior to the initial&#xD;
             dose of study medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James D Carlson, Pharm. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRACS Institute Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRACS Institute, Ltd.</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mpibiostudies.com</url>
    <description>Mylan Pharmaceuticals Inc. - Clinical Trial Results</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
    <description>Daily Med - posting of most recent submitted labelling to the Food and Drug Administration (FDA) and currently in use</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>Recalls, Market Withdrawals and Safety Alerts</description>
  </link>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>March 30, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>March 31, 2008</last_update_submitted>
  <last_update_submitted_qc>March 31, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Will Sullvan, Global Head of Product Risk and Safety Management</name_title>
    <organization>Mylan Inc.</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

